싸이토젠

217330KOSDAQ자연과학 및 공학 연구개발업

54.3 / 100

Reference Date: 2026-07-24

Financial Score17.0 / 40

News Sentiment21.3 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is undervalued vs. peers but the high debt ratio poses financial risk. Slightly down 1.2% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

CytoGen focuses on liquid biopsy platforms based on CTC (Circulating Tumor Cells) technology, offering services such as supporting anti-cancer drug development, precision medicine, and health supplement sales. Key business areas include companion diagnostics development with pharmaceutical companies, medical device distribution, and health supplement sales, while also expanding globally through research and international collaborations.

Number of Employees

39people

Average Salary

64.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 43.644.0Point

PBR

2.04Industry Average 2.524.0Point

In line with industry avg

ROE

-29.06Industry Average -32.093.5Point

Below industry avg

Debt Ratio

31.95Industry Average 7.310.0Point

4.4x industry avg (risky)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲190.7% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲16.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -38.7% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Positive
싸이토젠, 암 전이 막는 차단제 개발 착수… 신약 시장 정조준
싸이토젠이 암 전이 차단 신약 개발로 성장 가능성을 확대하며 긍정적인 시장 반응을 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (12%, downtrend)

Current 3,175Won52-week high 9,42052-week low 2,320

1-month return3.0Point

1m -1.24% (flat)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-06-26
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-26
Neutral주식등의대량보유상황보고서(일반)2026-06-26